NDAC Will Evaluate Trial Design, Labeling For Athlete’s Foot OTCs
This article was originally published in The Tan Sheet
Executive Summary
FDA's Nonprescription and Dermatologic & Ophthalmic Drugs advisory committees will discuss clinical trial design and future development programs for drugs treating interdigital Tinea pedis during their May 6-7 meeting in Rockville, MD
You may also be interested in...
OTC Athlete’s Foot Drugs Scheduled For FDA Advisory Committee Review
FDA's Nonprescription Drugs and Dermatologic & Ophthalmic Drugs advisory committees are scheduled to review OTCs used in treatment of interdigital tinea pedis at a May 6-7 meeting in Rockville, Md
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands